Concept and clinical application of platelet glycoprotein IIb/IIIa inhibition with abciximab (c7E3 Fab; ReoPro) for the prevention of acute ischemic syndromes

Clinical and Applied Thrombosis/Hemostasis

Volumn 3, Issue 4, 1997, Pages 256-266

  Anderson, H Vernon ^a   Jordan, Robert E ^b   Weisman, Harlan F ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b CENTOCOR INC   (United States)

Author keywords

Coronary revascularization; GP IIb IIIa receptor; Ischemia; Platelet aggregation

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG MECHANISM; DRUG MIXTURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; THROMBOCYTE AGGREGATION; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0031419410     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969700300407     Document Type: Article

References (41)

1. DeWood MA, Spores J, Notscke R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897.
2. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81.
3. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995;74:302.
4. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553.
5. Jordan RE, Wagner CL, Mascelli MA, et al. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet functions by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, ed. Adhesion Receptors as Therapeutic Targets. Baca Raton, FL: CRC Press; 1995:327.
6. George JN, Caen JP, Nurden AT. Glanzmann thrombasthenia: the spectrum in clinical disease. Blood 1990;75:1383.
7. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins Hb and/or IIIa. J Clin Invest 1983;72:325.
8. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991;614:193.
9. Plow EF, Marguerie G, Ginsberg M. Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol 1987;36:4035.
10. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993;5:864.
11. Choi ET, Engel L, Callow AD, et al. Inhibition of neointimal hyperplasia by blocking alpha-v/beta-3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994;19:125.
12. Coller BS, Scudder LE. Inhibition of a dog platelet function by in vivo infusion of F(ab′)2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 1985;66:1456.
13. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet GPIIb/IIIa receptor in an experimental animal model. Blood 1986;68:783.
14. Coller BS, Foils JD, Smith SR, et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GP IIb/IIIa receptor: correlation with bleeding time, platelet aggregation, and blockade of GP IIb/IIIa receptors. Circulation 1989;80:1766.
15. Bates ER, Walsh DG, Mu DX, et al. Sustained inhibition of the vessel wall-platelet interactions after deep coronary artery injury by temporary inhibition of the platelet glycoprotein IIb/IIIa receptor. Coronary Artery Dis 1992;3:67.
16. Mickelson JK, Simpson PJ, Lucchesi BR. Antiplatelet monoclonal F(ab')2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol 1989;21:393.
17. Bates ER, McGillen MJ, Mickelson JK, et al. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation 1991;84:2463.
18. Gold HK, Coller BS, Yasuda T, et al. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation. Circulation 1988;77: 670.
19. 2 fragment. J Cardiovasc Pharmacol 1994;23:194.
20. Yasuda T, Gold HK, Fallon JT, et al. Monoclonal antibody against the platelet GP IIb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue-type plasminogen activator in dogs. J Clin Invest 1988;81:1284.
21. Yasuda T, Gold HK, Leinbach RC, et al. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol 1990;16:1728.
22. Anderson HV, Revana M, Rosales O, et al. Intravenous administration of monoclonal antibody to the platelet GPIIb/IIIa receptor to treat abrupt closure during coronary angioplasty. Am J Cardiol 1992;69:1373.
23. Anderson HV, Kirkeeide RL, Krishnaswami A, et al. Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol 1994;23:1031.
24. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757.
25. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381.
26. Simoons ML, de Boer MJ, van den Brand MJBM, et al. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596.
27. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. New Engl J Med 1994;330:956.
28. Rao AK, Pratt C, Berks A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1.
29. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881.
30. Lincoff AM, Tcheng JE, Califf RM, et al. Standard versus low-dose-weight-adjusted heparin in patients treated with the platelet GP IIb/IIIa receptor antibody fragment abciximab (c7E3 FAB) during percutaneous coronary revascularization. PROLOG Investigators. Am J Cardiol 1997;79:286.
31. Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC Investigators. Am J Cardiol 1996;77:1045.
32. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882.
33. Boehrer JD, Kereiakes DJ, Navetta FI, et al. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. Am J Cardiol 1994;74:1166.
34. Weisman HF. ReoPro Clinical Development: Future Directions and Therapeutic Approaches. J Invasive Cardiol 1996;8:51B.
35. Ferguson JJ. EPILOG and CAPTURE trials halted because of positive interim results. Circulation 1996;93:637.
36. Mark DB, Talley JD, Topol EJ, et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high risk coronary angioplasty. Circulation 1996; 94:629.
37. George BS, Voorhees WD III, Roubin GS, et al. Multicenter investigation of coronary stenting to treat acute threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol 1993;22:135.
38. Hearn JA, King SB, Douglas JS, et al. Clinical and angiographic outcomes after coronary artery stenting for acute or threatened closure after percutaneous transluminal coronary angioplasty. Circulation 1993;88:2086.
39. Lincoff AM, Topol EJ, Chapekis AT, et al. Intracoronary stenting compared with conventional therapy for abrupt vessel closure complicating coronary angioplasty: a matched case-control study. J Am Coll Cardiol 1993;21:866.
40. Serruys PW, De Jaegere P, Kiemeneij F, et al. for the Benestent Study Group. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489.
41. Fischman DL, Leon MB, Bairn DS, et al. for the Stent Restenosis Investigators. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496.